In vitro cytotoxic mechanisms of Pt(O,O'-acac)(γ-acac)(DMS): mitochondrial dysfunction and impaired autophagy in U251
L Gaiaschi1, F De Luca1, C R Girelli2
1Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Abstract:
Glioblastoma stands as the deadliest primary brain malignancy in adults, primarily due to its resistance to conventional treatments and the restrictive nature of the blood-brain barrier (BBB). Cisplatin (CDDP), a widely used chemotherapeutic, demonstrates limited efficacy against glioblastoma owing to systemic toxicity and insufficient BBB penetration. To overcome these hurdles, we tested the platinum(II) complex [Pt(O,O'-acac)(γ-acac)(DMS)], indicated as Pt(acac)₂(DMS), known for its improved lipophilicity, ability to disrupt mitochondrial function, and reduced neurotoxic profile. Compared to CDDP, Pt(acac)₂(DMS) induced a targeted and prolonged cytotoxic response in U251 glioblastoma cells, promoting mitochondrial dysfunction, cell cycle arrest, and modulation of autophagy, while sparing primary human astrocytes. Our findings indicate that Pt(acac)₂(DMS) may overcome key limitations of cisplatin, including toxicity issues and resistance associated with autophagic adaptation, highlighting its promise as a potential therapeutic candidate for glioblastoma treatment.
Insights
A novel platinum complex, Pt(acac)₂(DMS), shows promise for treating glioblastoma. It effectively targets cancer cells, disrupts mitochondria, and avoids toxicity, unlike cisplatin.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Drug Discovery
Background:
- Glioblastoma is a lethal brain cancer with poor treatment outcomes.
- Cisplatin efficacy is limited by toxicity and poor blood-brain barrier (BBB) penetration.
- Developing new therapies to overcome glioblastoma resistance is critical.
Purpose of the Study:
- To evaluate the efficacy of a novel platinum(II) complex, Pt(acac)₂(DMS), against glioblastoma.
- To compare Pt(acac)₂(DMS) with cisplatin (CDDP) in terms of cytotoxicity and mechanism of action.
- To assess the safety profile of Pt(acac)₂(DMS) in non-cancerous cells.
Main Methods:
- In vitro testing of Pt(acac)₂(DMS) and CDDP on U251 glioblastoma cells and primary human astrocytes.
- Assessment of cytotoxicity, mitochondrial function, cell cycle progression, and autophagy.
- Evaluation of lipophilicity and neurotoxicity profiles.
Main Results:
- Pt(acac)₂(DMS) demonstrated superior and prolonged cytotoxicity against glioblastoma cells compared to CDDP.
- The novel complex induced mitochondrial dysfunction and cell cycle arrest in cancer cells.
- Pt(acac)₂(DMS) modulated autophagy and showed reduced toxicity to astrocytes.
- Improved lipophilicity and reduced neurotoxicity were observed for Pt(acac)₂(DMS).
Conclusions:
- Pt(acac)₂(DMS) overcomes key limitations of cisplatin, including toxicity and resistance mechanisms.
- This platinum complex represents a promising therapeutic candidate for glioblastoma treatment.
- Targeted disruption of mitochondrial function and autophagy modulation are key mechanisms of Pt(acac)₂(DMS).
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...